518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors
2021
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI